SCHERIPROCT COMBINATION PRODUCT SUPPOSITORY

Indications

• Epilepsy
• Bipolar disorder
• Seizure disorders

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations based on the condition being treated.

Mechanism of action

Carproate exerts its effects primarily through the inhibition of voltage-gated sodium channels and by increasing the availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. This action leads to decreased neuronal excitability and increased seizure threshold, thereby reducing the frequency of seizures.

Pharmacodynamics

The pharmacodynamics of carproate involve its influence on neurotransmitter systems, particularly the enhancement of GABAergic transmission. This results in a calming effect on the central nervous system. Additionally, the drug may modulate excitatory neurotransmitter activity, further contributing to its anticonvulsant and mood-stabilizing effects.

Pharmacokinetics

Carproate is well-absorbed after oral administration, with peak plasma concentrations typically achieved within 2 to 4 hours. It is highly protein-bound, primarily to albumin. The drug undergoes hepatic metabolism, primarily via glucuronidation, and has a half-life ranging from 8 to 20 hours, which can vary based on individual patient factors such as age and liver function. Excretion occurs predominantly through the urine, with a portion as unchanged drug and its metabolites.

Contra-indications

• Hypersensitivity to carproate or any of its components
• Severe hepatic impairment
• Active gastrointestinal bleeding or ulceration
• Severe renal impairment

Adverse effects

• Gastrointestinal disturbances such as nausea, vomiting, diarrhea
• Dizziness or headache
• Rash or allergic skin reactions
• Elevated liver enzymes
• Renal impairment
• Increased risk of bleeding

Interactions

• May enhance effects of anticoagulants
• Potential interaction with other NSAIDs, increasing risk of adverse effects
• Caution with medications that affect renal function
• May interact with antihypertensive medications, potentially reducing their effectiveness

Precautions

• Monitor liver function tests periodically
• Use with caution in patients with a history of gastrointestinal disease
• Caution in patients with cardiovascular disease or hypertension
• Use during prolonged therapy may require regular monitoring of renal function

Pregnancy

Carproate should be avoided during pregnancy due to potential risk of fetal harm. It is classified as a Category C drug.

Breast-feeding

Use with caution, as carproate may pass into breast milk. Consult a healthcare professional before use while breastfeeding.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Capsules
• Oral solution

Indications

• Local anesthesia for minor surgical procedures
• Topical anesthetic for skin and mucous membrane procedures
• Dental anesthesia

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines.

Mechanism of action

Cinchocaine functions by blocking both the initiation and conduction of nerve impulses. It decreases the permeability of the neuronal membrane to sodium ions through inhibition of sodium channels. This stabilizes the membrane and inhibits depolarization, leading to the failure of propagated action potentials and subsequent conduction blockade. The anesthetic action progressively develops in a nerve, increasing the threshold for electrical excitability, slowing impulse conduction, and decreasing the probability of propagation of the action potential.

Pharmacodynamics

As an amide-type local anesthetic, cinchocaine shares pharmacodynamic properties with other agents in its class, such as lidocaine. It provides a reversible blockade of nerve conduction, effectively numbing the area to which it is applied. Its onset and duration of action may vary based on concentration and the specific formulation used.

Pharmacokinetics

Cinchocaine is absorbed through mucous membranes and the skin, with its onset of action typically occurring within minutes. The duration of action can vary, often lasting for several hours. It is metabolized primarily in the liver and excreted through the kidneys. The pharmacokinetic profile may be influenced by factors such as the route of administration and individual patient characteristics.

Adverse effects

• Local irritation
• Allergic reactions
• Systemic toxicity (e.g., seizures, cardiac arrest)

Precautions

• Use with caution in patients with a history of hypersensitivity to local anesthetics
• Caution in patients with severe hepatic impairment

Pregnancy

Cinchocaine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is classified as a category B drug.

Breast-feeding

Cinchocaine is excreted in breast milk; caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Topical cream
• Gels
• Ointments

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Dermatological conditions (e.g., eczema, psoriasis)
• Allergic reactions
• Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
• Certain cancers (e.g., leukemia, lymphoma)

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in children.

Adults: Refer to the BNF for specific dosing guidelines based on condition and severity.

Mechanism of action

Prednisolone exerts its effects by binding to the glucocorticoid receptor in the cytoplasm, which then translocates to the nucleus. This complex interacts with glucocorticoid response elements in the DNA, leading to the modulation of gene expression. This results in decreased production of pro-inflammatory cytokines, inhibition of immune cell proliferation, and suppression of the inflammatory response.

Pharmacodynamics

Prednisolone demonstrates anti-inflammatory effects by reducing the infiltration of inflammatory cells and inhibiting the release of inflammatory mediators such as prostaglandins and leukotrienes. Its immunosuppressive actions are characterized by the inhibition of T-cell activation and the reduction of antibody production. The drug's effects are dose-dependent and can lead to both therapeutic benefits and potential adverse effects.

Pharmacokinetics

Prednisolone is well absorbed following oral administration, with peak plasma concentrations typically occurring within 1-2 hours. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system, producing active and inactive metabolites. The elimination half-life is approximately 2-3 hours, and the drug is primarily excreted in urine. Factors such as liver function and concurrent medications can affect its metabolism and clearance.

Contra-indications

• Systemic fungal infections
• Hypersensitivity to prednisolone or any of its components
• Live vaccines in immunocompromised patients

Adverse effects

• Increased susceptibility to infections
• Gastrointestinal disturbances
• Weight gain and fluid retention
• Hypertension
• Hyperglycemia
• Osteoporosis
• Mood changes and psychiatric disturbances
• Cushing's syndrome with prolonged use

Interactions

• Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal side effects
• Anticoagulants may have altered effects
• Diuretics may enhance potassium loss
• Vaccines may be less effective in immunosuppressed patients

Precautions

• Use with caution in patients with diabetes mellitus
• Monitor for signs of infection
• Gradual withdrawal is recommended after long-term therapy to avoid adrenal insufficiency
• Use with caution in patients with a history of peptic ulcer disease

Pregnancy

Prednisolone can be used during pregnancy if the benefits outweigh the risks. It is classified as Category C.

Breast-feeding

Prednisolone is excreted in breast milk, and caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Protect from light.

Formulations

• Tablets
• Oral solution
• Injection (intravenous and intramuscular)
• Topical formulations (creams and ointments)

Mechanism of action

Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade. ... PREVENT THE GENERATION & THE CONDUCTION OF THE NERVE IMPULSE. THEIR PRIMARY SITE OF ACTION IS THE CELL MEMBRANE. ... BLOCK CONDUCTION BY DECREASING OR PREVENTING THE TRANSIENT INCREASE IN THE PERMEABILITY OF EXCITABLE MEMBRANES TO NA IONS THAT IS NORMALLY PRODUCED BY A SLIGHT DEPOLARIZATION ... /LOCAL ANESTHETICS/ AS ANESTHETIC ACTION PROGRESSIVELY DEVELOPS IN A NERVE, THE THRESHOLD FOR ELECTRICAL EXCITABILITY GRADUALLY INCREASES, THE RATE OF RISE OF THE ACTION POTENTIAL DECLINES, IMPULSE CONDUCTION SLOWS, & THE SAFETY FACTOR FOR CONDUCTION DECREASES; THESE FACTORS DECREASE PROBABILITY OF PROPAGATION OF THE ACTION POTENTIAL, AND NERVE CONDUCTION FAILS. /LOCAL ANESTHETICS/ ... CAN BLOCK K ION CHANNELS. ... BLOCKADE OF CONDUCTION IS NOT ACCOMPANIED BY ANY LARGE OR CONSISTENT CHANGE IN RESTING MEMBRANE DUE TO BLOCK OF K ION CHANNELS. /LOCAL ANESTHETICS/ ... SITE AT WHICH LOCAL ANESTHETICS ACT, AT LEAST IN THEIR CHARGED FORM, IS ACCESSIBLE ONLY FROM THE INNER SURFACE OF THE MEMBRANE. ... LOCAL ANESTHETICS APPLIED EXTERNALLY FIRST MUST CROSS THE MEMBRANE BEFORE THEY CAN EXERT A BLOCKING ACTION. /LOCAL ANESTHETICS/ ... ACT ON ANY PART OF NERVOUS SYSTEM & ON EVERY TYPE OF NERVE FIBER. /LOCAL ANESTHETICS/

Pharmacodynamics

Dibucaine is an amide-type local anesthetic, similar to lidocaine.